Aehr Test Systems stands to benefit as testing takes a larger share of expanding semiconductor capex. Teradyne CEO Greg Smith says test's share of semiconductor capex rose from 6.4% in 2025 to 8.1% in the first eight months of 2026, with conditions favorable for prolonged ATE growth. Data-center reliability is pushing testing upstream from systems toward packages and wafers, where Aehr dominates wafer-level burn-in. Aehr lacks a dedicated CPU segment. x.com 

Aehr Test Systems' selloff has been excessive, despite concern about Teradyne expanding into burn-in, given where the two actually compete, as @LIWEI_TWCapital's comparison shows. x.com 

Aehr Test Systems' valuation looks ahead of its fundamentals after a strong turnaround quarter. Q4 FY2026 revenue rose 33% to $18.8 million with a return to GAAP profit, bookings hit a record $60.7 million and effective backlog topped $100.6 million. FY2027 guidance of $130-150 million implies 160-200% growth, so the post-earnings run prices in high expectations that depend on shipping FOX-XP systems on schedule without margin erosion. TRT is preferred for now. x.com  x.com 

Aehr Test Systems stands to benefit because testing is a bottleneck to scaling AI chips. Testing demand is about to surge. Investors did not question its price-to-sales ratio at 120, despite the current P/S objection. x.com  x.com 

Aehr Test Systems' thesis strengthened with its best report ever, though the stock's risk/reward is now impaired. The most important disclosure was that its lead AI customer has eliminated system-level burn-in and moved production entirely to Aehr's wafer-level systems. FY27 guidance of $130-150M far exceeded the $85M consensus. x.com 

Aehr Test Systems is unattractive near $100, at 22.5x sales and 112x forward earnings, even though it will very likely go above $100. Other burn-in names such as AEM Holdings look better placed to play catch-up. x.com 

Aehr Test Systems' AI wafer-level burn-in business is scaling, with a $22M follow-on order from its lead AI processor customer to expand capacity for high-volume production. That customer is already planning more capacity, and Aehr is expanding talks with other hyperscalers. The stock reached fresh all-time highs, and its recent strength looks like institutional accumulation. x.com  x.com  x.com 

Aehr Test Systems' lead hyperscale customer is expanding production with about $6M of follow-on Sonoma orders for a second-generation AI processor. These are production-capacity orders, not evaluations, and the customer expects the second processor eventually to exceed the volumes of the first, already in high-volume production. Teradyne's new burn-in on Titan HP overlaps only with package-level Sonoma work, not FOX-XP wafer-level burn-in that screens dies before costly CoWoS packaging. x.com 

Aehr remains a concentrated, expensive way to own wafer-level photonics burn-in: its 10-K says silicon-photonics customers primarily drove that revenue growth, and FY2027 guidance of $130m-$150m could nearly triple FY2026 sales, yet shares value it at about 20x the guide. Teradyne's acquired photonic-chip test business is not material to its much larger sales; Aehr's top five customers provided 70% of FY2026 revenue, so orders matter more than the headline CPO opportunity. x.com 

Aehr Test Systems captures more value than Trio-Tech because it sells proprietary burn-in equipment, while Trio-Tech sells consumable boards that go into competing equipment. Aehr's FOX-XP is the only validated wafer-level burn-in solution for silicon photonics transceivers, with multiple AI optical I/O wins and a patent moat, so it captures any migration to wafer-level testing. Its Sonoma package-level system won a record $41M hyperscaler order, and H2 FY26 bookings topped $92M. x.com